116 related articles for article (PubMed ID: 28102234)
41. Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure.
Lenneman CG
Curr Heart Fail Rep; 2014 Jun; 11(2):134-8. PubMed ID: 24682830
[TBL] [Abstract][Full Text] [Related]
42. Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.
García-González MJ; Jorge-Pérez P; Jiménez-Sosa A; Acea AB; Lacalzada Almeida JB; Ferrer Hita JJ
Cardiovasc Ther; 2015 Aug; 33(4):193-9. PubMed ID: 25959786
[TBL] [Abstract][Full Text] [Related]
43. [Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
MMW Fortschr Med; 2003 Feb; 145(8):57. PubMed ID: 12661451
[No Abstract] [Full Text] [Related]
44. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology.
Eur Heart J; 1997 May; 18(5):736-53. PubMed ID: 9152644
[No Abstract] [Full Text] [Related]
45. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial.
Fiuzat M; Wojdyla D; Pina I; Adams K; Whellan D; O'Connor CM
JACC Heart Fail; 2016 Feb; 4(2):109-115. PubMed ID: 26519996
[TBL] [Abstract][Full Text] [Related]
46. Heart failure: clinical problem and management issues.
Nicklas JM; Bleske BE; Van Harrison R; Hogikyan RV; Kwok Y; Chavey WE
Prim Care; 2013 Mar; 40(1):17-42. PubMed ID: 23402460
[TBL] [Abstract][Full Text] [Related]
47. Neuregulin-1/ErbB signaling: a druggable target for treating heart failure.
Xu Y; Li X; Zhou M
Curr Opin Pharmacol; 2009 Apr; 9(2):214-9. PubMed ID: 19070544
[TBL] [Abstract][Full Text] [Related]
48. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan -- report from the CHART Studies.
Ushigome R; Sakata Y; Nochioka K; Miyata S; Miura M; Tadaki S; Yamauchi T; Sato K; Onose T; Tsuji K; Abe R; Oikawa T; Kasahara S; Takahashi J; Shimokawa H;
Circ J; 2015; 79(11):2396-407. PubMed ID: 26356834
[TBL] [Abstract][Full Text] [Related]
49. Heart failure with preserved ejection fraction: controversies, challenges and future directions.
Zakeri R; Cowie MR
Heart; 2018 Mar; 104(5):377-384. PubMed ID: 29305560
[TBL] [Abstract][Full Text] [Related]
50. Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomised controlled trials.
Xin W; Wei W; Li X
Heart; 2012 Nov; 98(22):1620-5. PubMed ID: 22760864
[TBL] [Abstract][Full Text] [Related]
51. [The place of cardiac glycosides in the treatment of chronic heart failure. Part III. The DIG trial].
Sidorenko BA; Preobrazhenskiĭ DV; Sharoshina IA; Batyraliev TA; Pershukov IV; Makhmutkhodzhaev SA
Kardiologiia; 2005; 45(6):61-70. PubMed ID: 16007036
[TBL] [Abstract][Full Text] [Related]
52. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
[TBL] [Abstract][Full Text] [Related]
53. [Heart failure in coronary heart disease].
Hauf GF; Roskamm H
Internist (Berl); 1993 Oct; 34(10):953-60. PubMed ID: 8225845
[No Abstract] [Full Text] [Related]
54. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
Hwang IC; Kim YJ; Park JB; Yoon YE; Lee SP; Kim HK; Cho GY; Sohn DW
BMC Cardiovasc Disord; 2017 Jun; 17(1):150. PubMed ID: 28606099
[TBL] [Abstract][Full Text] [Related]
55. Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Upshaw JN; Konstam MA; Klaveren Dv; Noubary F; Huggins GS; Kent DM
Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27514751
[TBL] [Abstract][Full Text] [Related]
56. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure.
Gao R; Zhang J; Cheng L; Wu X; Dong W; Yang X; Li T; Liu X; Xu Y; Li X; Zhou M
J Am Coll Cardiol; 2010 May; 55(18):1907-14. PubMed ID: 20430261
[TBL] [Abstract][Full Text] [Related]
57. [Effects of recombined human neuregulin on the contractibility of cardiac muscles of rhesus monkeys with pacing-induced heart failure].
Li J; Gu XH; Duan JC; Zeng L; Li Y; Wang L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):105-8. PubMed ID: 17294740
[TBL] [Abstract][Full Text] [Related]
58. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
[TBL] [Abstract][Full Text] [Related]
59. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K
Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765
[TBL] [Abstract][Full Text] [Related]
60. Targeting heart failure with preserved ejection fraction: current status and future prospects.
Kanwar M; Walter C; Clarke M; Patarroyo-Aponte M
Vasc Health Risk Manag; 2016; 12():129-41. PubMed ID: 27143907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
